A toxicokinetic study to elucidate 3-hydroxybenzo(a)pyrene atypical urinary excretion profile following intravenous injection of benzo(a)pyrene in rats

Journal of Applied Toxicology

Volumn 30, Issue 5, 2010, Pages 402-410

  Marie, Caroline ^a,b   Bouchard, Michèle ^a   Heredia Ortiz, Roberto ^a   Viau, Claude ^a   Maître, Anne ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

3 hydroxybenzo(a)pyrene; Benzo(a)pyrene; Biomonitoring; Kinetics; Rats

Indexed keywords

3 HYDROXYBENZO[A]PYRENE; BENZO[A]PYRENE; 3-HYDROXYBENZO(A)PYRENE; BENZO[A]PYRENE DERIVATIVE; CARCINOGEN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FECES ANALYSIS; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN; TISSUE DISTRIBUTION; TOXICOKINETICS; URINALYSIS; URINARY EXCRETION; ANIMAL; AREA UNDER THE CURVE; DRUG EFFECTS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; AREA UNDER CURVE; BENZO(A)PYRENE; BENZOPYRENES; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 77955399262     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1511     Document Type: Article

References (42)

1. Angerer J, Ewers U, Wilhelm M. 2007. Human biomonitoring: state of the art. Int. J. Hyg. Environ. Health 210: 201-228.
2. Barbeau D, Marques M, Badouard C, Stoklov M, Maître A. 2008. Mise au point d'une méthode de dosage du 3-hydroxybenzo(a)pyrène urinaire afin d'évaluer l'exposition aux Hydrocarbures Aromatiques Polycycliques en population générale. Bull. Inform. Santé Environ. 19: 19 (Abstract).
3. Boffetta P, Jourenkova N, Gustavsson P. 1997. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8: 444-472.
4. Bouchard M, Viau C. 1995. Benzo(a)pyrenediolepoxide-hemoglobin adducts and 3-hydroxy-benzo(a)pyrene urinary excretion profiles in rats subchronically exposed to benzo(a)pyrene. Arch. Toxicol. 69: 540-546.
5. Bouchard M, Viau C. 1996. Urinary excretion kinetics of pyrene and benzo(a)pyrene metabolites following intravenous administration of the parent compounds or the metabolites. Toxicol. Appl. Pharmacol. 139: 301-309.
6. Bouchard M, Viau C. 1997. Urinary excretion of benzo[a]pyrene metabolites following intravenous, oral, and cutaneous benzo[a]pyrene administration. Can. J. Physiol. Pharmacol. 75: 185-192.
7. Bouchard M, Dodd C, Viau C. 1994. Improved procedure for the high-performance liquid chromatographic determination of monohydroxylated PAH metabolites in urine. J. Anal. Toxicol. 18: 261-264.
8. Bouchard M, Krishnan K, Viau C. 1998. Kinetics of tissue distribution and elimination of pyrene and 1-hydroxypyrene following intravenous administration of [14C]pyrene in rats. Toxicol. Sci. 46: 11-20. (Pubitemid 29014079)
9. Fan R, Dong Y, Zhang W, Wang Y, Yu Z, Sheng G, Fu J. 2006. Fast simultaneous determination of urinary 1-hydroxypyrene and 3-hydroxybenzo[a] pyrene by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 836: 92-97.
10. Forster K, Preuss R, Rossbach B, Bruning T, Angerer J, Simon P. 2008. 3-Hydroxybenzo[a]pyrene in the urine of workers with occupational exposure to polycyclic aromatic hydrocarbons in different industries. Occup. Environ. Med. 65: 224-229.
11. Gendre C, Lafontaine M, Morele Y, Payan JP, Simon P. 2002. Relationship between urinary levels of 1-hydroxypyrene and 3-hydroxybenz[a] pyrene for workers exposed to polycyclic aromatic hydrocarbons. Polycyclic Aromat. Compd 22: 761-769.
12. Gendre C, Lafontaine M, Delsaut P, Simon P. 2004. Exposure to polycyclic aromatic hydrocarbons and excretion of urinary 3-hydroxybenzo[a] pyrene (3-OHBaP): assesment of an appropriate sampling time. Polycyclic Aromat. Compd 24: 433-439.
13. Gill PE, Murray W. 1978. Algorithms for the solution of the nonlinear least-squares problems. SIAM J. Numer. Anal. 15: 997-992.
14. Godschalk RW, Ostertag JU, Moonen EJ, Neumann HA, Kleinjans JC, Van Schooten FJ. 1998. Aromatic DNA adducts in human white blood cells and skin after dermal application of coal tar. Cancer Epidemiol. Biomarkers Prev. 7: 767-773.
15. Godschalk RW, Moonen EJ, Schilderman PA, Broekmans WM, Kleinjans JC, Van Schooten FJ. 2000. Exposure-route-dependent DNA adduct formation by polycyclic aromatic hydrocarbons. Carcinogenesis 21: 87-92.
16. Gosselin NH, Bouchard M, Brunet RC, Dumoulin MJ, Carrier G. 2005. Toxicokinetic modeling of parathion and its metabolites in humans for the determination of biological reference values. Toxicol. Mech. Meth. 15: 33-52.
17. Jacob J, Seidel A. 2002. Biomonitoring of polycyclic aromatic hydrocarbons in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 778: 31-47.
18. 14C-3,4-benzopyrene after administration to mice and rats. J. Natl Cancer Inst. 24: 541-555.
19. Lafontaine M, Gendre C, Delsaut P, Simon P. 2004. Urinary 3-htydroxybenzo[a]pyrene as a biomarker of exposure to polycyclic aromatic hydrocarbons: an approach for determining a biological limite value. Polycyclic Aromat. Compd 24: 441-450.
20. Lafontaine M, Champmartin C, Simon P, Delsaut P, Funck-Brentano C. 2006. 3-Hydroxybenzo[a]pyrene in the urine of smokers and nonsmokers. Toxicol. Lett. 162: 181-185.
21. Maître A, Badouard C, Pauthier E, Marques M, Le Gall L, Stoklov M. 2008a. Cartographie d'exposition professionnelle aux Hydrocarbures Aromatiques Polycycliques (HAP): intérêt de la fiche de renseignements sur l'activité professionnelle. Arch. Mal. Prof. 69: 328-329.
22. Maître A. 2008b Méthodes d'évaluation de l'exposition aux Hydrocarbures Aromatiques Polycycliques (HAP) et étude des mélanges. Bull. Inform. Santé Environ. 19: 6-8.
23. Marie C, Maître A, Douki T, Gateau M, Tarantini A, Ravanat JL. 2007. Influence of the metabolic properties of human cells on the kinetic of formation of the major benzo[a]pyrene DNA adducts. J. Appl. Toxicol. 28: 579-590.
24. Mastrangelo G, Fadda E, Marzia V. 1996. Polycyclic aromatic hydrocarbons and cancer in man. Environ. Health Perspect. 104: 1166-1170.
25. Mitchell CE. 1982. Distribution and retention of benzo(A)pyrene in rats after inhalation. Toxicol. Lett. 11: 35-42.
26. Mitchell CE. 1983. The metabolic fate of benzo[a]pyrene in rats after inhalation. Toxicology 28: 65-73.
27. Moir D, Viau A, Chu I, Withey J, McMullen E. 1998. Pharmacokinetics of benzo[a]pyrene in the rat. J. Toxicol. Environ. Health A 53: 507-530.
28. Mollière M, Foth H, Kahl R, Kahl GF. 1987. Comparison of benzo(a)pyrene metabolism in isolated perfused rat lung and liver. Arch. Toxicol. 60: 270-277.
29. Prough RA, Patrizi VW, Okita RT, Masters BS, Jakobsson SW. 1979. Characteristics of benzo(a)pyrene metabolism by kidney, liver, and lung microsomal fractions from rodents and humans. Cancer Res. 39: 1199-1206.
30. Ramesh A, Inyang F, Hood DB, Archibong AE, Knuckles ME, Nyanda AM. 2001a. Metabolism, bioavailability, and toxicokinetics of benzo(α) pyrene in F-344 rats following oral administration. Exp. Toxic. Pathol. 53: 275-290.
31. Simon P, Lafontaine M, Delsaut P, Morele Y, Nicot T. 2000. Trace determination of urinary 3-hydroxybenzo[a]pyrene by automated column-switching high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Applic. 748: 337-348.
32. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Cogliano V. 2005. Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol. 6: 931-932.
33. Tzekova A, Leroux S, Viau C. 2004. Electrophilic tissue burden in male Sprague-Dawley rats following repeated exposure to binary mixtures of polycyclic aromatic hydrocarbons. Arch. Toxicol. 78: 106-113.
34. Uziel M, Haglund R. 1988. Persistence of benzo[a]pyrene and 7,8-dihydro-7,8-dihydroxybenzo[a] pyrene in Fischer 344 rats: time distribution of total metabolites in blood, urine and feces. Carcinogenesis 9: 233-238.
35. Van Aubel RA, Masereeuw R, Russel FG. 2000. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 279: F216-F232.
36. Van Schooten FJ, Moonen EJ, Van der Wal L, Levels P, Kleinjans JC. 1997. Determination of polycyclic aromatic hydrocarbons (PAH) and their metabolites in blood, feces, and urine of rats orally exposed to PAH contaminated soils. Arch. Environ. Contam. Toxicol. 33: 317-322.
37. Wang JJ, Frazer DG, Stone S, Goldsmith T, Law B, Moseley A, Simpson J, Afshari A, Lewis DM. 2003. Urinary benzo[a]pyrene and its metabolites as molecular biomarkers of asphalt fume exposure characterized by microflow LC coupled to hybrid quadrupole time-of-flight mass spectrometry. Anal. Biochem. 322: 79-88.
38. Wang Y, Zhang W, Dong Y, Fan R, Sheng G, Fu J. 2005. Quantification of several monohydroxylated metabolites of polycyclic aromatic hydrocarbons in urine by high-performance liquid chromatography with fluorescence detection. Anal. Bioanal. Chem. 383: 804-809.
39. Weyand EH, Bevan DR. 1986. Benzo(a)pyrene disposition and metabolism in rats following intratracheal instillation. Cancer Res. 46: 5655-5661.
40. Withey JR, Shedden J, Law FC, Abedini S. 1993. Distribution of benzo[a] pyrene in pregnant rats following inhalation exposure and a comparison with similar data obtained with pyrene. J. Appl. Toxicol. 13: 193-202.
41. Wright SH, Dantzler WH. 2004. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 84: 987-1089.
42. Xue W, Warshawsky D. 2005. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. Toxicol. Appl. Pharmacol. 206: 73-93.